Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration

Journal of Clinical Pharmacology

Volumn 37, Issue 5, 1997, Pages 405-415

  Zimmerman, James J ^a   Kahan, Barry D ^b  

^a WYETH AYERST RESEARCH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; NIFEDIPINE; PLACEBO; PREDNISONE; RAPAMYCIN;

ADULT; AREA UNDER THE CURVE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE; MEAN RESIDENCE TIME; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0031008434     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04318.x     Document Type: Review

References (29)

1. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL: A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369:756-758.
2. Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White DJ, Thiru S: Rapamycin for immunosuppression in organ allografting (letter). Lancet 1989;2:227.
3. Stepkowski SM, Chen H, Daloze P, Kahan BD: Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplantation 1991; 51:22-26.
4. Tu Y, Stepkowski SM, Chou TC, Kahan BD: The synergistic effects of cyclosporine, sirolimus and brequinar on heart allograft survival in mice. Transplantation 1995;59:177-183.
5. Knight R, Ferraresso M, Serino F, Katz SM, Lewis R, Kahan BD: Brief communication: low dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993;55:947-948.
6. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
7. Kahan BD, Gibbons S, Tejpal N, Stepkowski S, Chou TC: Synergistic interaction of cyclosporine and rapamycin to inhibit immune performances for normal human peripheral blood lymphocytes in vitro. Transplantation 1991;51:232-239.
8. Murgia MG, Jordan S, Kahan BD: The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant-patients. Kidney Int 1996;49:209-216.
9. Christians U, Sattler M, Schiebel HM, Kruse D, Radeke HH, Linck A, Sewing KF: Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos 1992;20:186-191.
10. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF: Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-761.
11. Kolars JC, Stetson PL, Rush BD, Ruwart MS, Schmiedlin-Ron P, Duell EA, et al: Cyclosporine metabolism by P450IIIA in rat enterocytes - another determinant of oral bioavailability? Transplantation 1992;53:596-602.
12. Guengerich FP: Characterization of human microsomal cytochrome P-450 enzymes. Annu Rev Pharmacol Toxicol 1989;29: 241-264.
13. Lindholm A, Kahan BD: Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993;54:205-218.
14. Brown SCW, O'Reilly PH: lodohexol clearance for the determination of glomerular filtration rate in clinical practice: evidence for a new gold standard. J Urol 1991;146:675-679.
15. Lewis R, Podbielski J, Sprayberry S, Munsell M, Katz S, Rubin M, et al: Stability of renal allograft glomerular filtration rate associated with long-term use of cyclosporine A. Transplantation 1993;55:1014-1017.
16. Gibaldi M, Perrier D; Pharmacokinetics. Second Edition. New York: Marcel Decker, 1982.
17. Pfeffer M: Estimation of mean residence time from data obtained when multiple-dosing steady state has been reached. J Pharm Sci 1984;73:854-856.
18. Gough K, Hutchison M, Keene O: Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Information J 1995;29:1039-1048.
19. Guidance: Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design. Rockville, MD: Office of Generic Drugs, Food and Drug Administration, Public Health Service, US Department of Health and Human Services, 1992.
20. Draper NR, Smith H: Applied Regression Analysis. New York: John Wiley and Sons, 1966;26-32.
21. SAS User's Guide: Statistics. Cary, NC: SAS Institute, 1989.
22. Johnson EM, Zimmerman J, Duderstadt K, Chambers J, Serenson AL, Granger DK, et al: A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 1996;28:987.
23. Wacher VJ, Wu CY, Benet LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-134.
24. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ: Bioavailability of cyclosporin with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-457.
25. Huang JD, Su SF: Effect of quinidine on digoxin absorption in the rat: interaction on P-glycoprotein in the small intestine (abstract). FASEB J 1995;9:A691.
26. Kahan BD. Overview: individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985;40:457-476.
27. Venkataramanan R, Jain A, Cadoff E, Warty V, Iwasaki K, Nagase K, et al: Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc 1990;22:52-56.
28. Niederberger W, Lemaire M, Maurer G, Nussbaumer K, Wagner O: Distribution and binding of cyclosporine in blood and tissues. Transplant Proc 1983;15:2419.
29. Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, et al: Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995;57:281-290.